Haleon vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Haleon PLC (HLN.LSE)

Q3 202630 Jul – 24 Sep 2026

▲2▼1

Haleon buys US shelf space and GLP-1 tie-ins to lift growth

US shelf-space wins lift market share Haleon won prime shelf spots at Walmart and Target by offering lower prices and promotions, lifting its US consumer-health share from 11.4% to 12%. More visibility for Sensodyne and Centrum should support sales, though the profit cost of those deals is undisclosed.
This is the main new force behind Haleon's US growth push and share gains.
GLP-1 side-effect products drive store sales Haleon's products for GLP-1 weight-loss drug side effects, placed in dedicated CVS sections, produced an average 24% sales lift per store. With about 11% of Americans using GLP-1 drugs, this opens a new demand channel and talks are underway with Walmart and Target.
It shows a fresh, measurable sales driver tied to a fast-growing consumer trend.
First-half profit beat but sales growth lags Haleon beat profit expectations and raised its dividend, but organic revenue growth of 2.6% is below its 4%-6% medium-term target, with weak European demand and a 6.5% drop in respiratory sales. Shares fell as investors doubted the sales outlook.
It captures the core tension: solid earnings versus sluggish underlying sales growth.
Debt buyback uses cash and adds costs Haleon repurchased $1.34 billion of 2027 notes at a premium, reducing future debt but using cash and incurring costs. This is a minor capital-structure move that slightly weighs on near-term financial flexibility.
It is a new capital action that affects Haleon's cash position and debt profile.

August 202630 Jul – 24 Sep 2026

▲2▼1

Haleon buys US shelf space and GLP-1 tie-ins to lift growth

US shelf-space wins lift market share Haleon won prime shelf spots at Walmart and Target by offering lower prices and promotions, lifting its US consumer-health share from 11.4% to 12%. More visibility for Sensodyne and Centrum should support sales, though the profit cost of those deals is undisclosed.
This is the main new force behind Haleon's US growth push and share gains.
GLP-1 side-effect products drive store sales Haleon's products for GLP-1 weight-loss drug side effects, placed in dedicated CVS sections, produced an average 24% sales lift per store. With about 11% of Americans using GLP-1 drugs, this opens a new demand channel and talks are underway with Walmart and Target.
It shows a fresh, measurable sales driver tied to a fast-growing consumer trend.
First-half profit beat but sales growth lags Haleon beat profit expectations and raised its dividend, but organic revenue growth of 2.6% is below its 4%-6% medium-term target, with weak European demand and a 6.5% drop in respiratory sales. Shares fell as investors doubted the sales outlook.
It captures the core tension: solid earnings versus sluggish underlying sales growth.
Debt buyback uses cash and adds costs Haleon repurchased $1.34 billion of 2027 notes at a premium, reducing future debt but using cash and incurring costs. This is a minor capital-structure move that slightly weighs on near-term financial flexibility.
It is a new capital action that affects Haleon's cash position and debt profile.

Latest30 Jul – 24 Sep 2026

▲2▼1

Haleon buys US shelf space and GLP-1 tie-ins to lift growth

US shelf-space wins lift market share Haleon won prime shelf spots at Walmart and Target by offering lower prices and promotions, lifting its US consumer-health share from 11.4% to 12%. More visibility for Sensodyne and Centrum should support sales, though the profit cost of those deals is undisclosed.
This is the main new force behind Haleon's US growth push and share gains.
GLP-1 side-effect products drive store sales Haleon's products for GLP-1 weight-loss drug side effects, placed in dedicated CVS sections, produced an average 24% sales lift per store. With about 11% of Americans using GLP-1 drugs, this opens a new demand channel and talks are underway with Walmart and Target.
It shows a fresh, measurable sales driver tied to a fast-growing consumer trend.
First-half profit beat but sales growth lags Haleon beat profit expectations and raised its dividend, but organic revenue growth of 2.6% is below its 4%-6% medium-term target, with weak European demand and a 6.5% drop in respiratory sales. Shares fell as investors doubted the sales outlook.
It captures the core tension: solid earnings versus sluggish underlying sales growth.
Debt buyback uses cash and adds costs Haleon repurchased $1.34 billion of 2027 notes at a premium, reducing future debt but using cash and incurring costs. This is a minor capital-structure move that slightly weighs on near-term financial flexibility.
It is a new capital action that affects Haleon's cash position and debt profile.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.